Avalon Pharmaceuticals, of Germantown, recently announced that it received a deficiency notice from the Nasdaq Stock Market, telling the company it is not in compliance with the Nasdaq Marketplace Rule.
According to the Nasdaq, the company’s stockholders’ equity did not meet the minimum of $10 million required for continued listing on the Nasdaq Global Market. The notification has no immediate effect on the Nasdaq listing or trading of the company’s common stock.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.